4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone has been researched along with Leukemia in 1 studies
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone: Inhibitor of phosphodiesterases.
Leukemia: A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Burde, R | 1 |
| Seifert, R | 1 |
| Buschauer, A | 1 |
| Schultz, G | 1 |
1 other study available for 4-(3-butoxy-4-methoxybenzyl)-2-imidazolidinone and Leukemia
| Article | Year |
|---|---|
Histamine inhibits activation of human neutrophils and HL-60 leukemic cells via H2-receptors.
Topics: 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone; Alprostadil; Bucladesine; Cell Aggregation; Cyclic A | 1989 |